According to CyanVac subsidiary Blue Lake Biotechnology, the FDA has granted Fast Track designation for the company’s BLB-201 intranasal vaccine against respiratory syncytial virus (RSV) in children under 2 and adults over 60. The vaccine is based on an attenuated strain of canine parainfluenza virus (PIV5).
In March 2022, Blue Lake announced that the FDA had cleared its IND for BLB-201, and the company says that it is currently preparing a Phase 1 trial.
Blue Lake CEO Biao He commented, “FDA’s granting of Fast Track designation for BLB-201 reflects the urgent need for an RSV vaccine. It is encouraging that FDA recognizes the potential of our vaccine to address this need for children under 2 years old as well as for older adults. This RSV vaccine candidate expands our intranasal vaccine pipeline, and builds on our experience in developing a clinical stage intranasal COVID-19 vaccine.”
Read the Blue Lake Biotechnology press release.
